Sotorasib: First Approval
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Surprisingly, in 2021, after unremitting efforts, a milestone was achieved: the KRASG12C inhibitor sotorasib was approved by the FDA for a specific subgroup of patients with non-small cell lung cancer (NSCLC),10”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [10]
In the citing paper
“In recent years, two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved by the United States Food and Drug Administration (US FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), 8,9 but not in mCRC as monotherapy as to date.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R. R., & O’Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 156
Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.321 · Cited by 30
Skoulidis, F., Li, B. T., Govindan, R., Dy, G. K., Shapiro, G., Bauml, J., Schuler, M. H., Addeo, A., Kato, T., Besse, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9003 · Cited by 24 · cited 1×
“The clinical benefit of sotorasib was also seen regardless of age (< 65 vs ≥ 65 years), ECOG PS (0 vs 1), metastatic disease (yes vs no), prior lines of therapy (1 vs ≥ 2), prior anti-PD-1/PD-L1 therapy (yes vs no), TP53 co-mutation (wild-type vs mutant), STK11 comutation (wild-type vs mutant), KEAP1 co-mutation (wild…”
BackgroundReck, M., Spira, A. I., Besse, B., Wolf, J. M., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1730 · Cited by 21
Saiki, A. Y., Gaida, K., Rex, K., Achanta, P., Miguel, T. S., Koppada, N., Bagal, D., Lanman, B. A., Foti, R. S., McCarter, J. D., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4484 · Cited by 15
Spira, A. I., Wilson, F. H., Shapiro, G. I., Dooms, C., Fontecedro, A. C., Esaki, T., Barlési, F., Cocks, K., Trigg, A., Stevinson, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9057 · Cited by 13
Hong, D. S., Strickler, J. H., Fakih, M., Falchook, G. S., Li, B. T., Durm, G. A., Burns, T. F., Ramalingam, S. S., Goldberg, S. B., Frank, R. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps2669 · Cited by 10
Research works printed but not linked: 9
- Amgen. Amgen announces first clinical data evaluating novel investigational KRASG12C inhibitor AMG 510 at ASCO 2019 [media release]. 3 Jun 2019. https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019.
- Amgen. Amgen's sotorasib granted breakthrough therapy designation for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation [media release]. 8 Dec 2020. https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation.
- Amgen. FDA grants sotorasib priority review designation for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer [media release]. 16 Feb 2021. https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer.
- Cardona P Simiens M Purkis J An open-label study to evaluate the effect of omeprazole on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-009] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Cardona P Spring M Purkis J An open-label study to evaluate the effect of single and multiple doses of rifampin on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-010] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Vuu I Simiens M Purkis J A phase I, open-label study to evaluate drug-drug interactions between metformin and sotorasib (AMG 510) in healthy subjects [abstract no. PIII-018] Clin Pharmacol Ther 2021 109 Suppl. 1 S50
- Cardona P Spring M Purkis J An open-label study to evaluate the effect of sotorasib (AMG 510) on digoxin pharmacokinetics in healthy subjects [abstract no. PII-011] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Guardant Health. Guardant360® CDx receives FDA approval as first and only liquid biopsy companion diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C inhibitor for use in advanced non-small cell lung cancer [media release]. 28 May 2021. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx.
- QIAGEN. QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours and expand precision medicine options in lung cancer [media release]. 28 May 2021. https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2021/QIAGEN-Launches-First-FDA-approved-Tissue-Companion-Diagnostic-to-Identify-the-KRAS-G12C-Mutation-in-NSCLC-Tumours-and-Expand-Precision-Medicine-Options-in-Lung-Cancer/default.aspx.
Cited by
Items 201–267 of 267
Zhai, Y., Niu, S., Qiu, T., Yuan, Y., Yan, Y., Hu, R., He, X., & Xu, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576015 · Cited by 1
“Until recently, the breakthrough was made by AMG510 (Sotorasib) and MRTX849 (Adagrasib) targeting the G12C mutation, showing marked clinical responses across multiple tumor types (Blair 2021; Ou et al. 2022).”
BackgroundDrug-development Strategy for Undruggable Targets Using a Novel Target Degradation Technology CANDDY
Miyamoto‐Sato, E., Imanishi, S., & Huang, L. (2022) · Journal of The Society of Japanese Women Scientists · doi:10.5939/sjws.22005
Otero‐Alén, B., Estévez-Pérez, L. S., Hermida-Romero, M. T., Reguera-Arias, A., García‐Campelo, R., Bravos, M. D. L. T., & Concha, Á. (2022) · Cancers · doi:10.3390/cancers14143323
Targeting Vulnerabilities in Cell State and Calcium Signaling for the Treatment of Lung Cancer
Jones, C. A. (2022) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.11424
The discovery and treatment of Sotorasib in cancer immune
Bu, X., & Wang, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1187
“According to the prescribing information in the US, Sotorasib may cause hepatotoxicity and potentially fatal interstitial lung disease (ILD)/pneumonia [6].”
BackgroundSotorasib and other drugs comparison in treating non-small cell lung cancer
Ren, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1256
“FDA approved Sotorasib as a targeted therapy drug that targets NSCLC in May 2021 [2].”
BackgroundKhan, H. Y., Nagasaka, M., Li, Y., Aboukameel, A., Uddin, M. H., Sexton, R. E., Bannoura, S. F., Mzannar, Y., Hallak, M. N. A., Kim, S. H., et al. (2023) · doi:10.1158/2767-9764.c.6550541
zhang, L., Chen, W., Wei, H., & Yu, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2794257/v1
Synthesis of 1,4-Diacyl-2-Methylpiperazine Derivatives
王, 博. (2023) · Hans Journal of Chemical Engineering and Technology · doi:10.12677/hjcet.2023.134028
Targeted Therapies for Pancreatic Cancer
Maitra, A. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch151
Corey, E. J., & Wu, Y. (2023) · Wiley eBooks · doi:10.1002/9781394207145.ch21
Advances in Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma
梁, 亚. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102187
Method Development and Validation for the Determination of Sotorasib by LC-MS/MS Technique
Sunkara, P. K., Chaganty, S., & Ramakrishna, K. (2023) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.14.4.14
Wang, J., Shen, H., Jiang, Y., & Meng, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3787479/v1
Lihua Qin1, 2. (2024) · International Journal of Frontiers in Medicine · doi:10.25236/ijfm.2024.060404
Drug Reactions and Radiation Effects
Elliott, D. F., & Zander, D. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93548-7.00019-2
Flores, R., Nihalani, R., Umur, S., Vigneault, F., & Novak, R. (2025) · Research Square · doi:10.21203/rs.3.rs-6130021/v1
Mechanism of Action and Research Progress of Drugs Targeting KRAS G12-Mutant Tumors
郑, 金. (2025) · World Journal of Cancer Research · doi:10.12677/wjcr.2025.152011
Klußmann, M., Matijass, M., & Neundorf, I. (2025) · ChemBioChem · doi:10.1002/cbic.202401076
Choudhary, R., Das, N., Nayak, B., Tiwari, R., Malekar, A., & Sahare, V. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638365059250707070424
Aplicabilidad de Sotorasib y Adagrasib: actualidad y futuras proyecciones
Durazno, K. D. R. Z. (2025) · Polo del Conocimiento · doi:10.23857/pc.v10i8.10259
Khan, H. Y., Hallak, M. N. A., Aboukameel, A., Bannoura, S. F., Uddin, M. H., Aboukameel, A. A., Alkan, F. K., Çağlayan, A. B., Alkan, H. K., Bao, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.21.689857
Ahmed, A. (2025) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2025.26.11.4195
“For comparative purposes, a molecular docking study assessed the interaction between G007-LK (Tankyrase inhibitors) [59].”
Studying the chemosensitizing effect of Pirfenidone in non-small cell lung cancer cell lines
Branco, H. I. D. F. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/dc65-2f13
Targeting mitochondrial function as a therapeutic approach for pancreatic ductal adenocarcinoma
Amparo, A. M. (2023) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/n34c-3288
KRAS: role in cancer and targeted therapies
Αλεξανδρή, Φ. Ε., & Αλεξανδρή, Φ. Ε. (2024) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.41461
IncRNAs como reguladores de la señalización a través de la cascada de ERK
Molina Carreño, D. (2024) · UCrea (University of Cantabria)
CFAフラグメントライブラリーを用いた細胞代謝フェノタイプスクリーニングによるコバレントリガンド探索
井上, 和. (2023) · Institutional Repositories DataBase (IRDB)
The current status of medicine development for precision therapy and diagnosis targeting KRASG12C
Zhang, C., Wang, F., & Tian, G.-L. (2026) · Biophysics Reports · doi:10.52601/bpr.2026.250060
朱, 含. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161317
Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors
Baig, M. H., Jo, Y. S., Nale, S. D., Kim, C. J., Park, J., Ha, J., Moon, B., Ryu, S., & Dong, J.-J. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2609342
Protein-protein interaction inhibitors in cancer
Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4
Dissecting KRAS Functional Heterogeneity in Patient-Derived Lung Adenocarcinoma Models
Rosen, J. C. (2025) · TSpace (University of Toronto)
A Novel Approach to Discover Cryptic Drug-Binding Pockets In Silico
Kwak, H. J. (2025) · TSpace (University of Toronto)
Frisch, A., Martin, E., Cannon, T. L., Wadlow, R. C., Raghavan, S., Sen, T., & Karim, N. A. (2026) · Current Oncology · doi:10.3390/curroncol33030148
Manoharan, S., Santhakumar, A., & Perumal, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44121-9.00010-x
Innovative therapeutic approaches
Sharma, V., Saini, S., Minocha, N., & Pandey, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44041-0.00022-2
Yan, Y., Wang, Y., Zhang, X., Ao, J., Zhang, Z., Wang, N., Hao, X., Ning, F., Zhang, L., & Tang, L. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109917
Fu, W., Yan, Y., Tian, F., Shu, C.-H., Yang, F., Xia, Y., Chen, X., Chen, J., Jiang, Y., Cui, R., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109956
Awn, A. K., Arean, A. G., Findakly, S. B., Yasin, Y. S., & Jumaa, A. H. (2026) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2026.11.1.9-22
“A molecular docking study was conducted for comparative purposes to assess the interaction between Sotorasib, a “RAS GTPase inhibitor” [63, 64].”
Chen, J., Liu, X., Wang, R., Li, J., Xu, Z., Yang, B., He, Q., Yang, X., Yan, H., & Luo, P. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118078
Kumar, P., Henry, M., Pelesko, J., Desai, B., Weh, M. T., Kakumanu, R., Liu, M., Siqueira, N. S. N., Velde, R. V., Marusyk, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.16.725647
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
Zhu, Y., Zhang, C., Li, M., Ai, L., Xu, F., Yu, Y., Yu, S., Xu, X., Liu, Q., Zhu, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03838-1
Stamey, A. G. (2024) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ks9g-rn42
Cancer Cells, Oncogenes, and Therapeutic Interventions
Minden, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-20529-2_19
Park, J.-Y., Kwak, C.-H., Chang, Y.-C., & Kim, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1878931
Chen, T., & Ho, S. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag635
“…membrane proteins (MPs), transporters implicated in tumorigenesis, and immunomodulatory targets; many of these target classes lack the canonical binding pockets typically required for conventional small-molecule inhibition yet may participate in malignant progression (Blair 2021, Gulezian et al .”
72120 Role of cross-coupling reactions in drug discovery and development
Jalli, D. P., Rallabandi, N. C., & Kumar, R. (2026) · De Gruyter eBooks · doi:10.1515/9783111850825-021
α,β-Unsaturated carbonyl-based anticancer agents targeting cysteine residues
Chen, C.-H., Zhan, N., Xie, H., Zhang, Y., Zhou, Z., Liu, X., Liang, Y., Lu, X., & Liu, Z. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118500
การกลายพันธุ์ของยีน KRAS ในมะเร็งปอดชนิดเซลล์ไม่เล็ก
Wongsirisin, P. (2022) · Thai cancer journal
Blockade of mutant RAS oncogenic signaling: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109669
Transcriptomic Analysis of Drug-Resistant Lung Adenocarcinoma
Farry, S. (2024) · Otago University Research Archive (University of Otago)
Hoersting, N., Hense, J., Schüler, M., Guberina, N., Guberina, M., Opitz, M., & Wiesweg, M. (2026) · Oncology Research and Treatment · doi:10.1159/ort/aecag005
“Sotorasib and adagrasib are globally approved for advanced or metastatic KRAS G12C -mutated NSCLC after progression under at least one prior line of therapy [2, 3].”
Determinants of cysteine coverage by chemoproteomicsPreprint
Riziotis, I. G., Wilders, H., Cairoli, A., Lambert, H., Dark, J., Biggs, G. S., Cawood, E. E., McCarthy, W. J., Nightingale, L., Magariños, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.12.758458
A Pan-KRAS-Targeted PET Probe for Noninvasive Quantitative Imaging of KRAS Expression
Guo, Q., Wang, D., Du, J., 刘金剑, Yang, L., & Liu, J. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c01137
Recent advances in scaffold-based KRAS G12C inhibitors: SAR and biological evaluation insights
Bhattacharjee, T., Kumar, A., Singh, T. G., & Bhatia, R. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00337k
BindingDB (2025) · UC San Diego · doi:10.7270/q2vm4hvh
BindingDB (2024) · UC San Diego · doi:10.7270/q2m61qmd
BindingDB (2026) · UC San Diego · doi:10.7270/q26w9gxr
BindingDB (2026) · UC San Diego · doi:10.7270/q2t4401d
BindingDB (2025) · UC San Diego · doi:10.7270/q2668jtz
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Abdelhakeem, A. A. F., Ganatra, N., Gul, K., Saxena, H., Mohammed, N., Ashraf, A., Jones, J. C., Carr, R., Bekaii‐Saab, T., Borad, M. J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01863-x
Xie, H., Wang, G., 原志庆, Li, Y., & Liu, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218931
Chen, Q., Li, Y., Niu, J., Huang, C., Xu, Y., Song, J., & Zhang, S. (2026) · Medicinal Research Reviews · doi:10.1002/med.70122
Metadata
- Authors
- Blair, H. A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Blair, Hannah A.
- Venue
- Drugs
- Published
- 2021-08-06
- Volume
- 81
- Issue
- 13
- Pages
- 1573-1579
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8531079
- OpenAlex
- W3193019540
- Cited by
- 241
- References
- 11
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 53 · 2023: 46 · 2022: 53 · 2021: 5
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-10-23)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- sotorasib, KRAS G12C mutation, non-small cell lung cancer, drug approval, accelerated approval, colorectal cancer, solid tumors, drug development milestones
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Lung Neoplasms, Piperazines, Pyridines, Pyrimidines, United States, United States Food and Drug Administration, Drug Approval, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

